email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
1126 - 1140
of 3630 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
Next
NovoCodex Reports Positive Data from ADC for Gastric Cancer
$5.00
Available
CBMG Raises $120 Million for Clinical Trials of Cellular Immunotherapies
$5.00
Available
iX Signs Up CRPCC to Distribute Sublingual ED Therapy in China
$5.00
Available
Bio-Thera Partners with Intract to Develop Oral mAb for GI Disease
$5.00
Available
Newsoara Bio Enters $171 Million Agreement for Oncolytic Viruses
$5.00
Available
Worg Pharma Acquires Apitope's Autoimmune Platform and Pipeline
$5.00
Available
Innovent Signs $267 Million Deal for Novel Anti-Inflammatory Candidate
$5.00
Available
Anji Pharma Closes $70 Million Series B for US-China Drug In-licensing
$5.00
Available
Salubris Acquires China Rights to Therapy for Obesity, NASH and Diabetes
$5.00
Available
Harbour BioMed Starts Phase III Trial of mAb for Myasthenia Gravis
$5.00
Available
Broncus Completes $200 Million Hong Kong IPO for Pulmonary Devices
$5.00
Available
Akeso Files for China Approval of PD-1/CTLA-4 for Cervical Cancer
$5.00
Available
Impact Uses Cyclia Platform to Validate Targetivity of Oncology Candidates
$5.00
Available
HighTide Says Lead Drug Effective for NASH and Type2 Diabetes
$5.00
Available
Hutchmed and Junshi Start Phase III trial of Sulanda/Tuoyi Combination
$5.00
Available